Elevance Health, Inc. operates a health benefits and healthcare services platform built around affiliated health plans and the Carelon services business. Recurring company news covers Health Benefits results, premium yields, medical-cost trends, Medicaid, Medicare Advantage and employer group membership, and Carelon activity in pharmacy services, behavioral health, value-based care, care delivery, clinical, home health and complex care solutions.
Company updates also address small and midsize employer benefit offerings such as Balanced Funding and MEWAs, primary-care recognition and value-based provider programs, partnerships tied to family and community health, annual and quarterly financial guidance, and leadership changes across Health Benefits and Carelon.
Elevance Health (NYSE: ELV) received indicative credit ratings from AM Best for securities under its recently filed shelf registrations, with stable outlooks. The ratings are bbb+ for senior unsecured issues, bbb for subordinated issues and bbb- for preferred stock issues, all categorized as Good. AM Best withdrew ratings on the expired previous shelf registration.
Financial leverage was 40.8% at September 30, 2026, against a long-term 40% target range. Earnings before interest and taxes covered interest expense more than six times in 2025 and through the third quarter of 2026. AM Best assessed liquidity and financial flexibility as good, supported by commercial paper, parent-company cash and a revolving credit facility.
Elevance Health (NYSE: ELV) appointed Jeff Park as President of Carelon, effective December 1, 2026, to lead the business.
Park most recently served as President of Waltz Health and continued leading that business after its merger with EVERSANA. His previous senior leadership roles included positions at OptumRx, Catamaran, WellDyneRx and Diplomat Pharmacy. Elevance Health said Carelon under Park will focus on strengthening operational performance, scaling its solutions and lowering the total cost of care.
Elevance Health (NYSE: ELV) raised its full-year 2026 diluted earnings guidance to at least $22.00 per share after reporting third-quarter results. Quarterly operating revenue rose 0.7% to $50.4 billion. Diluted earnings per share increased 17.9% to $6.27; adjusted diluted earnings were $6.99. Results included a $1.85-per-share net non-operating benefit.
The company raised adjusted earnings guidance to at least $29.00 per share and operating cash flow guidance to at least $6.5 billion. Its benefit expense ratio improved 70 basis points to 90.6%, but operating margin fell to 2.5% from 2.6%. Health Benefits operating gain declined to $0.4 billion from $0.6 billion, while Carelon operating gain rose 17% to $0.9 billion. Medical membership fell by 487,000 year over year to approximately 44.9 million. Elevance expects at least 12% adjusted earnings growth in 2027 from a baseline of at least $26.75 per share.
Elevance Health (ELV) will release its third quarter 2026 financial results on October 21, 2026, before a management conference call. Results will be released at 6:00 a.m. EDT, followed by a call and live webcast at 8:30 a.m. EDT to review results and the outlook. A webcast replay will be available from 11:30 a.m. EDT that day through November 20, 2026.
Elevance Health (NYSE: ELV) announced affiliated Medicare Advantage offerings for coverage beginning January 1, 2027, including expanded plans for chronic conditions.
The portfolio includes Dual Eligible Special Needs Plans for eligible members receiving both Medicare and Medicaid, and Chronic Condition Special Needs Plans for eligible members with certain chronic conditions. The company says these offerings are designed to support more coordinated care and personalized assistance. Many eligible plans make covered allowances available through a single Benefits Prepaid Card. Benefits, costs, provider networks, eligibility and availability vary by plan and location. Medicare’s Annual Enrollment Period runs from October 15 through December 7, 2026.
Elevance Health (NYSE: ELV) announced enhancements to its connected cancer care model to make treatment simpler, more personalized, and easier to navigate. Using advanced analytics and clinical support, the company seeks to identify patients earlier, guide them through complex decisions, and improve care coordination.
Through its Cancer Care Engagement (CCE) program, Elevance Health uses predictive analytics and certified oncology navigators, achieving an 84% engagement rate and associated reductions in avoidable inpatient admissions for Medicare Advantage and commercial members. Digital tools, remote monitoring, and 24/7 support have been associated with a 66% decrease in chemotherapy side-effect hospitalizations and a 25% reduction in 30-day readmissions, while Oncology Provider Enablement Clinicians work with oncologists to improve pathway adherence and reduce drug waste and emergency room visits.
Elevance Health (NYSE: ELV) reported 2Q 2026 operating revenue of $49.8 billion, up 0.8% year over year, with diluted EPS of $6.71 and adjusted diluted EPS of $7.45, supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit.
The company raised full-year 2026 diluted EPS guidance to at least $20.10 and adjusted diluted EPS guidance to at least $27.00, and increased operating cash flow guidance to at least $6.0 billion. Operating gain fell to $1.8 billion with a 3.5% margin, versus $2.4 billion and 4.9% a year earlier. Health Benefits revenue rose to $42.7 billion but operating gain declined to $0.9 billion, while Carelon revenue grew 6% to $19.2 billion with operating gain of $0.9 billion.
Operating cash flow was $1.9 billion in the quarter. Elevance repurchased 0.7 million shares for $234 million and paid a quarterly dividend of $1.72 per share, with $5.3 billion remaining under its share repurchase authorization. The Board’s Audit Committee declared a third quarter 2026 dividend of $1.72 per share.
Elevance Health (NYSE:ELV) will release its second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. EDT.
Management will discuss results and outlook on a conference call and live webcast at 8:30 a.m. EDT, with a replay available until August 14, 2026.
Elevance Health (NYSE:ELV) published a Public Policy Institute study on No Surprises Act payment disputes for planned procedures. Analyzing over 7,300 disputes, researchers found providers won 89.5% of claim lines and average IDR awards near $40,000, often tens to hundreds of times typical in-network or Medicare rates.
The median IDR award exceeded in-network rates by more than 50x, and awards for these procedures rose 43% between 2024 and 2025, raising concerns that arbitration may be increasing out-of-network costs for employers and families.
Elevance Health (NYSE:ELV) and the Impact Fitness Foundation partnered with Thomas Carr Howe Middle School in Indianapolis to unveil a transformed fitness and strength training space. The project, tied to the Elevance Health Women’s Fort Myers Tipoff, marks the fifth consecutive year of supporting Indianapolis schools through community fitness initiatives.
The renovation added new flooring, fitness equipment, storage, and organizational upgrades. The space will host expanded strength and conditioning programs, open gym time, and student-athlete development, with a focus on creating opportunities for young people, especially girls, to build confidence, leadership, and lifelong wellness habits.